Response to long-term lamivudine treatment in patients infected with hepatitis B virus genotypes A, B, and C
Response to lamivudine treatment longer than 1 year was compared in 15 patients persistently infected with hepatitis B virus (HBV) genotype A, 38 with genotype B, and 449 with genotype C. Patients with genotype A were younger (median age 37 [range 24–49] vs. 47 [24–67] or 44 [18–73], P = 0.015), pos...
Gespeichert in:
| Veröffentlicht in: | Journal of medical virology 2006-10, Vol.78 (10), p.1276-1283 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1283 |
|---|---|
| container_issue | 10 |
| container_start_page | 1276 |
| container_title | Journal of medical virology |
| container_volume | 78 |
| creator | Kobayashi, Mariko Suzuki, Fumitaka Akuta, Norio Suzuki, Yoshiyuki Arase, Yasuji Ikeda, Kenji Hosaka, Tetsuya Sezaki, Hitomi Kobayashi, Masahiro Iwasaki, Satomi Sato, Junko Watahiki, Sachiyo Miyakawa, Yuzo Kumada, Hiromitsu |
| description | Response to lamivudine treatment longer than 1 year was compared in 15 patients persistently infected with hepatitis B virus (HBV) genotype A, 38 with genotype B, and 449 with genotype C. Patients with genotype A were younger (median age 37 [range 24–49] vs. 47 [24–67] or 44 [18–73], P = 0.015), possessed hepatitis B e antigen (HBeAg) more frequently (73% vs. 21% or 56%, P |
| doi_str_mv | 10.1002/jmv.20701 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_20545460</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>20545460</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4221-6406f135391d0d2108aa0773d767db6f91e58a8aef7f63ed2bd1ebd59d2b2a923</originalsourceid><addsrcrecordid>eNp1kM1v1DAQxS0EokvLgX8A-UIlpKYdO4kdH7urfoCWIqHycbO88aR1SZzUdrbsf0_KLvTEaZ5mfm-e9Ah5w-CYAfCTu259zEECe0ZmDJTIFEj2nMyAFSITgpV75FWMdwBQKc5fkj0mFJe8UjPSfsE49D4iTT1te3-TJQwdbU3n1qN1ftoHNKlDn6jzdDDJTTJOusE6oaUPLt3SW3w8JBfpnK5dGCO9Qd-nzYCRnh7R-RE13tLFAXnRmDbi693cJ1_Pz64Xl9ny88WHxekyqwvOWSYKEA3Ly1wxC5YzqIwBKXMrhbQr0SiGZWUqg41sRI6WryzDlS3VpLhRPN8nh9u_Q-jvR4xJdy7W2LbGYz9GzaEsykLABL7fgnXoYwzY6CG4zoSNZqAfq9VTtfpPtRP7dvd0XHVon8hdlxPwbgeYWJu2CcbXLj5xFSgli3LiTrbcg2tx8_9E_fHTt7_R2dbhYsJf_xwm_NRC5rLU368utJrnP67Pl1Jf5r8BZZKfJg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>20545460</pqid></control><display><type>article</type><title>Response to long-term lamivudine treatment in patients infected with hepatitis B virus genotypes A, B, and C</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Kobayashi, Mariko ; Suzuki, Fumitaka ; Akuta, Norio ; Suzuki, Yoshiyuki ; Arase, Yasuji ; Ikeda, Kenji ; Hosaka, Tetsuya ; Sezaki, Hitomi ; Kobayashi, Masahiro ; Iwasaki, Satomi ; Sato, Junko ; Watahiki, Sachiyo ; Miyakawa, Yuzo ; Kumada, Hiromitsu</creator><creatorcontrib>Kobayashi, Mariko ; Suzuki, Fumitaka ; Akuta, Norio ; Suzuki, Yoshiyuki ; Arase, Yasuji ; Ikeda, Kenji ; Hosaka, Tetsuya ; Sezaki, Hitomi ; Kobayashi, Masahiro ; Iwasaki, Satomi ; Sato, Junko ; Watahiki, Sachiyo ; Miyakawa, Yuzo ; Kumada, Hiromitsu</creatorcontrib><description><![CDATA[Response to lamivudine treatment longer than 1 year was compared in 15 patients persistently infected with hepatitis B virus (HBV) genotype A, 38 with genotype B, and 449 with genotype C. Patients with genotype A were younger (median age 37 [range 24–49] vs. 47 [24–67] or 44 [18–73], P = 0.015), possessed hepatitis B e antigen (HBeAg) more frequently (73% vs. 21% or 56%, P < 0.001) and HBV DNA in higher levels (8.6 [6.1–8.7] vs. 6.5 [<3.7–8.7] or 6.5 [<3.7–8.7] log genome equivalents (LGE)/ml, P = 0.024) than those with genotype B or C. During lamivudine, YMDD mutants (89% vs. 53% or 42%, P = 0.0001) and breakthrough hepatitis developed more often (47% vs. 21% or 29%, P = 0.023) in patients with genotype A than B or C. YMDD mutants elicited more frequently in patients with genotype A than B or C who were positive (82% [9/11] vs. 25% [2/8] or 48% [117/245], P = 0.037) or negative for HBeAg (75% [3/4] vs. 30% [9/30] or 33% [68/204], P = 0.003). HBeAg (hazard ratio 2.1 [95% confidence interval 1.53–2.92], P < 0.001) and genotype A (2.78 [1.08–7.12], P = 0.034) enhanced the emergence of YMDD mutants by the Cox proportional hazard model. The risk for breakthrough hepatitis was increased by the baseline alanine aminotransferase level <500 IU/L (2.56 [1.82–5.50], P = 0.018), HBeAg (2.11 [1.40–3.16], P < 0.001), cirrhosis (1.92 [1.24–2.97], P = 0.004) and HBV DNA ≥8.0 LGE/ml (1.57 [1.04–2.36], P = 0.03); it was influenced by genotypes only in patients with HBeAg. In conclusion, HBV genotypes help in predicting response to long‐term lamivudine treatment and development of YMDD mutants in patients with chronic hepatitis B. J. Med. Virol. 78:1276–1283, 2006. © 2006 Wiley‐Liss, Inc.]]></description><identifier>ISSN: 0146-6615</identifier><identifier>EISSN: 1096-9071</identifier><identifier>DOI: 10.1002/jmv.20701</identifier><identifier>PMID: 16927289</identifier><identifier>CODEN: JMVIDB</identifier><language>eng</language><publisher>Hoboken: Wiley Subscription Services, Inc., A Wiley Company</publisher><subject>Administration, Oral ; Adolescent ; Adult ; Aged ; Biological and medical sciences ; chronic hepatitis ; cirrhosis ; Disease Progression ; Female ; Fundamental and applied biological sciences. Psychology ; Genetic Markers ; Genome, Viral ; Genotype ; genotypes ; Hepatitis B virus ; Hepatitis B virus - classification ; Hepatitis B virus - drug effects ; Hepatitis B virus - genetics ; Hepatitis B, Chronic - diagnosis ; Hepatitis B, Chronic - drug therapy ; Hepatitis B, Chronic - virology ; Hospitals, Urban ; Human viral diseases ; Humans ; Infectious diseases ; lamivudine ; Lamivudine - administration & dosage ; Lamivudine - adverse effects ; Lamivudine - pharmacology ; Lamivudine - therapeutic use ; Male ; Medical sciences ; Microbiology ; Middle Aged ; Miscellaneous ; Mutation ; Proportional Hazards Models ; Reverse Transcriptase Inhibitors - administration & dosage ; Reverse Transcriptase Inhibitors - adverse effects ; Reverse Transcriptase Inhibitors - therapeutic use ; Time Factors ; Tokyo ; Treatment Outcome ; Viral diseases ; Viral hepatitis ; Virology</subject><ispartof>Journal of medical virology, 2006-10, Vol.78 (10), p.1276-1283</ispartof><rights>Copyright © 2006 Wiley‐Liss, Inc.</rights><rights>2006 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4221-6406f135391d0d2108aa0773d767db6f91e58a8aef7f63ed2bd1ebd59d2b2a923</citedby><cites>FETCH-LOGICAL-c4221-6406f135391d0d2108aa0773d767db6f91e58a8aef7f63ed2bd1ebd59d2b2a923</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fjmv.20701$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fjmv.20701$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=18099745$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16927289$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kobayashi, Mariko</creatorcontrib><creatorcontrib>Suzuki, Fumitaka</creatorcontrib><creatorcontrib>Akuta, Norio</creatorcontrib><creatorcontrib>Suzuki, Yoshiyuki</creatorcontrib><creatorcontrib>Arase, Yasuji</creatorcontrib><creatorcontrib>Ikeda, Kenji</creatorcontrib><creatorcontrib>Hosaka, Tetsuya</creatorcontrib><creatorcontrib>Sezaki, Hitomi</creatorcontrib><creatorcontrib>Kobayashi, Masahiro</creatorcontrib><creatorcontrib>Iwasaki, Satomi</creatorcontrib><creatorcontrib>Sato, Junko</creatorcontrib><creatorcontrib>Watahiki, Sachiyo</creatorcontrib><creatorcontrib>Miyakawa, Yuzo</creatorcontrib><creatorcontrib>Kumada, Hiromitsu</creatorcontrib><title>Response to long-term lamivudine treatment in patients infected with hepatitis B virus genotypes A, B, and C</title><title>Journal of medical virology</title><addtitle>J. Med. Virol</addtitle><description><![CDATA[Response to lamivudine treatment longer than 1 year was compared in 15 patients persistently infected with hepatitis B virus (HBV) genotype A, 38 with genotype B, and 449 with genotype C. Patients with genotype A were younger (median age 37 [range 24–49] vs. 47 [24–67] or 44 [18–73], P = 0.015), possessed hepatitis B e antigen (HBeAg) more frequently (73% vs. 21% or 56%, P < 0.001) and HBV DNA in higher levels (8.6 [6.1–8.7] vs. 6.5 [<3.7–8.7] or 6.5 [<3.7–8.7] log genome equivalents (LGE)/ml, P = 0.024) than those with genotype B or C. During lamivudine, YMDD mutants (89% vs. 53% or 42%, P = 0.0001) and breakthrough hepatitis developed more often (47% vs. 21% or 29%, P = 0.023) in patients with genotype A than B or C. YMDD mutants elicited more frequently in patients with genotype A than B or C who were positive (82% [9/11] vs. 25% [2/8] or 48% [117/245], P = 0.037) or negative for HBeAg (75% [3/4] vs. 30% [9/30] or 33% [68/204], P = 0.003). HBeAg (hazard ratio 2.1 [95% confidence interval 1.53–2.92], P < 0.001) and genotype A (2.78 [1.08–7.12], P = 0.034) enhanced the emergence of YMDD mutants by the Cox proportional hazard model. The risk for breakthrough hepatitis was increased by the baseline alanine aminotransferase level <500 IU/L (2.56 [1.82–5.50], P = 0.018), HBeAg (2.11 [1.40–3.16], P < 0.001), cirrhosis (1.92 [1.24–2.97], P = 0.004) and HBV DNA ≥8.0 LGE/ml (1.57 [1.04–2.36], P = 0.03); it was influenced by genotypes only in patients with HBeAg. In conclusion, HBV genotypes help in predicting response to long‐term lamivudine treatment and development of YMDD mutants in patients with chronic hepatitis B. J. Med. Virol. 78:1276–1283, 2006. © 2006 Wiley‐Liss, Inc.]]></description><subject>Administration, Oral</subject><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Biological and medical sciences</subject><subject>chronic hepatitis</subject><subject>cirrhosis</subject><subject>Disease Progression</subject><subject>Female</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Genetic Markers</subject><subject>Genome, Viral</subject><subject>Genotype</subject><subject>genotypes</subject><subject>Hepatitis B virus</subject><subject>Hepatitis B virus - classification</subject><subject>Hepatitis B virus - drug effects</subject><subject>Hepatitis B virus - genetics</subject><subject>Hepatitis B, Chronic - diagnosis</subject><subject>Hepatitis B, Chronic - drug therapy</subject><subject>Hepatitis B, Chronic - virology</subject><subject>Hospitals, Urban</subject><subject>Human viral diseases</subject><subject>Humans</subject><subject>Infectious diseases</subject><subject>lamivudine</subject><subject>Lamivudine - administration & dosage</subject><subject>Lamivudine - adverse effects</subject><subject>Lamivudine - pharmacology</subject><subject>Lamivudine - therapeutic use</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Microbiology</subject><subject>Middle Aged</subject><subject>Miscellaneous</subject><subject>Mutation</subject><subject>Proportional Hazards Models</subject><subject>Reverse Transcriptase Inhibitors - administration & dosage</subject><subject>Reverse Transcriptase Inhibitors - adverse effects</subject><subject>Reverse Transcriptase Inhibitors - therapeutic use</subject><subject>Time Factors</subject><subject>Tokyo</subject><subject>Treatment Outcome</subject><subject>Viral diseases</subject><subject>Viral hepatitis</subject><subject>Virology</subject><issn>0146-6615</issn><issn>1096-9071</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kM1v1DAQxS0EokvLgX8A-UIlpKYdO4kdH7urfoCWIqHycbO88aR1SZzUdrbsf0_KLvTEaZ5mfm-e9Ah5w-CYAfCTu259zEECe0ZmDJTIFEj2nMyAFSITgpV75FWMdwBQKc5fkj0mFJe8UjPSfsE49D4iTT1te3-TJQwdbU3n1qN1ftoHNKlDn6jzdDDJTTJOusE6oaUPLt3SW3w8JBfpnK5dGCO9Qd-nzYCRnh7R-RE13tLFAXnRmDbi693cJ1_Pz64Xl9ny88WHxekyqwvOWSYKEA3Ly1wxC5YzqIwBKXMrhbQr0SiGZWUqg41sRI6WryzDlS3VpLhRPN8nh9u_Q-jvR4xJdy7W2LbGYz9GzaEsykLABL7fgnXoYwzY6CG4zoSNZqAfq9VTtfpPtRP7dvd0XHVon8hdlxPwbgeYWJu2CcbXLj5xFSgli3LiTrbcg2tx8_9E_fHTt7_R2dbhYsJf_xwm_NRC5rLU368utJrnP67Pl1Jf5r8BZZKfJg</recordid><startdate>200610</startdate><enddate>200610</enddate><creator>Kobayashi, Mariko</creator><creator>Suzuki, Fumitaka</creator><creator>Akuta, Norio</creator><creator>Suzuki, Yoshiyuki</creator><creator>Arase, Yasuji</creator><creator>Ikeda, Kenji</creator><creator>Hosaka, Tetsuya</creator><creator>Sezaki, Hitomi</creator><creator>Kobayashi, Masahiro</creator><creator>Iwasaki, Satomi</creator><creator>Sato, Junko</creator><creator>Watahiki, Sachiyo</creator><creator>Miyakawa, Yuzo</creator><creator>Kumada, Hiromitsu</creator><general>Wiley Subscription Services, Inc., A Wiley Company</general><general>Wiley-Liss</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7U9</scope><scope>H94</scope></search><sort><creationdate>200610</creationdate><title>Response to long-term lamivudine treatment in patients infected with hepatitis B virus genotypes A, B, and C</title><author>Kobayashi, Mariko ; Suzuki, Fumitaka ; Akuta, Norio ; Suzuki, Yoshiyuki ; Arase, Yasuji ; Ikeda, Kenji ; Hosaka, Tetsuya ; Sezaki, Hitomi ; Kobayashi, Masahiro ; Iwasaki, Satomi ; Sato, Junko ; Watahiki, Sachiyo ; Miyakawa, Yuzo ; Kumada, Hiromitsu</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4221-6406f135391d0d2108aa0773d767db6f91e58a8aef7f63ed2bd1ebd59d2b2a923</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Administration, Oral</topic><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Biological and medical sciences</topic><topic>chronic hepatitis</topic><topic>cirrhosis</topic><topic>Disease Progression</topic><topic>Female</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Genetic Markers</topic><topic>Genome, Viral</topic><topic>Genotype</topic><topic>genotypes</topic><topic>Hepatitis B virus</topic><topic>Hepatitis B virus - classification</topic><topic>Hepatitis B virus - drug effects</topic><topic>Hepatitis B virus - genetics</topic><topic>Hepatitis B, Chronic - diagnosis</topic><topic>Hepatitis B, Chronic - drug therapy</topic><topic>Hepatitis B, Chronic - virology</topic><topic>Hospitals, Urban</topic><topic>Human viral diseases</topic><topic>Humans</topic><topic>Infectious diseases</topic><topic>lamivudine</topic><topic>Lamivudine - administration & dosage</topic><topic>Lamivudine - adverse effects</topic><topic>Lamivudine - pharmacology</topic><topic>Lamivudine - therapeutic use</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Microbiology</topic><topic>Middle Aged</topic><topic>Miscellaneous</topic><topic>Mutation</topic><topic>Proportional Hazards Models</topic><topic>Reverse Transcriptase Inhibitors - administration & dosage</topic><topic>Reverse Transcriptase Inhibitors - adverse effects</topic><topic>Reverse Transcriptase Inhibitors - therapeutic use</topic><topic>Time Factors</topic><topic>Tokyo</topic><topic>Treatment Outcome</topic><topic>Viral diseases</topic><topic>Viral hepatitis</topic><topic>Virology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kobayashi, Mariko</creatorcontrib><creatorcontrib>Suzuki, Fumitaka</creatorcontrib><creatorcontrib>Akuta, Norio</creatorcontrib><creatorcontrib>Suzuki, Yoshiyuki</creatorcontrib><creatorcontrib>Arase, Yasuji</creatorcontrib><creatorcontrib>Ikeda, Kenji</creatorcontrib><creatorcontrib>Hosaka, Tetsuya</creatorcontrib><creatorcontrib>Sezaki, Hitomi</creatorcontrib><creatorcontrib>Kobayashi, Masahiro</creatorcontrib><creatorcontrib>Iwasaki, Satomi</creatorcontrib><creatorcontrib>Sato, Junko</creatorcontrib><creatorcontrib>Watahiki, Sachiyo</creatorcontrib><creatorcontrib>Miyakawa, Yuzo</creatorcontrib><creatorcontrib>Kumada, Hiromitsu</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>Journal of medical virology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kobayashi, Mariko</au><au>Suzuki, Fumitaka</au><au>Akuta, Norio</au><au>Suzuki, Yoshiyuki</au><au>Arase, Yasuji</au><au>Ikeda, Kenji</au><au>Hosaka, Tetsuya</au><au>Sezaki, Hitomi</au><au>Kobayashi, Masahiro</au><au>Iwasaki, Satomi</au><au>Sato, Junko</au><au>Watahiki, Sachiyo</au><au>Miyakawa, Yuzo</au><au>Kumada, Hiromitsu</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Response to long-term lamivudine treatment in patients infected with hepatitis B virus genotypes A, B, and C</atitle><jtitle>Journal of medical virology</jtitle><addtitle>J. Med. Virol</addtitle><date>2006-10</date><risdate>2006</risdate><volume>78</volume><issue>10</issue><spage>1276</spage><epage>1283</epage><pages>1276-1283</pages><issn>0146-6615</issn><eissn>1096-9071</eissn><coden>JMVIDB</coden><abstract><![CDATA[Response to lamivudine treatment longer than 1 year was compared in 15 patients persistently infected with hepatitis B virus (HBV) genotype A, 38 with genotype B, and 449 with genotype C. Patients with genotype A were younger (median age 37 [range 24–49] vs. 47 [24–67] or 44 [18–73], P = 0.015), possessed hepatitis B e antigen (HBeAg) more frequently (73% vs. 21% or 56%, P < 0.001) and HBV DNA in higher levels (8.6 [6.1–8.7] vs. 6.5 [<3.7–8.7] or 6.5 [<3.7–8.7] log genome equivalents (LGE)/ml, P = 0.024) than those with genotype B or C. During lamivudine, YMDD mutants (89% vs. 53% or 42%, P = 0.0001) and breakthrough hepatitis developed more often (47% vs. 21% or 29%, P = 0.023) in patients with genotype A than B or C. YMDD mutants elicited more frequently in patients with genotype A than B or C who were positive (82% [9/11] vs. 25% [2/8] or 48% [117/245], P = 0.037) or negative for HBeAg (75% [3/4] vs. 30% [9/30] or 33% [68/204], P = 0.003). HBeAg (hazard ratio 2.1 [95% confidence interval 1.53–2.92], P < 0.001) and genotype A (2.78 [1.08–7.12], P = 0.034) enhanced the emergence of YMDD mutants by the Cox proportional hazard model. The risk for breakthrough hepatitis was increased by the baseline alanine aminotransferase level <500 IU/L (2.56 [1.82–5.50], P = 0.018), HBeAg (2.11 [1.40–3.16], P < 0.001), cirrhosis (1.92 [1.24–2.97], P = 0.004) and HBV DNA ≥8.0 LGE/ml (1.57 [1.04–2.36], P = 0.03); it was influenced by genotypes only in patients with HBeAg. In conclusion, HBV genotypes help in predicting response to long‐term lamivudine treatment and development of YMDD mutants in patients with chronic hepatitis B. J. Med. Virol. 78:1276–1283, 2006. © 2006 Wiley‐Liss, Inc.]]></abstract><cop>Hoboken</cop><pub>Wiley Subscription Services, Inc., A Wiley Company</pub><pmid>16927289</pmid><doi>10.1002/jmv.20701</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0146-6615 |
| ispartof | Journal of medical virology, 2006-10, Vol.78 (10), p.1276-1283 |
| issn | 0146-6615 1096-9071 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_20545460 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Administration, Oral Adolescent Adult Aged Biological and medical sciences chronic hepatitis cirrhosis Disease Progression Female Fundamental and applied biological sciences. Psychology Genetic Markers Genome, Viral Genotype genotypes Hepatitis B virus Hepatitis B virus - classification Hepatitis B virus - drug effects Hepatitis B virus - genetics Hepatitis B, Chronic - diagnosis Hepatitis B, Chronic - drug therapy Hepatitis B, Chronic - virology Hospitals, Urban Human viral diseases Humans Infectious diseases lamivudine Lamivudine - administration & dosage Lamivudine - adverse effects Lamivudine - pharmacology Lamivudine - therapeutic use Male Medical sciences Microbiology Middle Aged Miscellaneous Mutation Proportional Hazards Models Reverse Transcriptase Inhibitors - administration & dosage Reverse Transcriptase Inhibitors - adverse effects Reverse Transcriptase Inhibitors - therapeutic use Time Factors Tokyo Treatment Outcome Viral diseases Viral hepatitis Virology |
| title | Response to long-term lamivudine treatment in patients infected with hepatitis B virus genotypes A, B, and C |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-29T20%3A50%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Response%20to%20long-term%20lamivudine%20treatment%20in%20patients%20infected%20with%20hepatitis%20B%20virus%20genotypes%20A,%20B,%20and%20C&rft.jtitle=Journal%20of%20medical%20virology&rft.au=Kobayashi,%20Mariko&rft.date=2006-10&rft.volume=78&rft.issue=10&rft.spage=1276&rft.epage=1283&rft.pages=1276-1283&rft.issn=0146-6615&rft.eissn=1096-9071&rft.coden=JMVIDB&rft_id=info:doi/10.1002/jmv.20701&rft_dat=%3Cproquest_cross%3E20545460%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=20545460&rft_id=info:pmid/16927289&rfr_iscdi=true |